Association of ideal body weight–normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
research has been conducted on the relationship between the dose of cyclophosphamide given after transplantation and the development of chronic graft-versus-host disease in patients who are overweight or obese. the dose of cyclophosphamide is being normalized based on ideal body weight. this study examines how this normalized dose may be associated with chronic graft-versus-host disease in these patients.